WeVote
Log In

Bill

Bill

S 1720

Due Process Continuity of Care Act

119th Congress Introduced by Bill Cassidy and 4 co-sponsors

Bill S 1720 aimed to launch a campaign educating women on hormone replacement therapy for menopause, enhancing informed health decisions, but was vetoed.

Introduced in Senate
0
WeVote Research Nonpartisan
Bill Summary · S 1720

Summary of Bill S 1720

Bill Overview

  • Bill Number: S 1720
  • Title: Establishes an awareness campaign on the use of hormone replacement therapy in treating the symptoms of perimenopause and menopause
  • Status: VETOED MEMO.47
  • Introduced: January 13, 2025
  • Classification: Bill

Purpose and Intent

The primary aim of Bill S 1720 is to create an awareness campaign focused on hormone replacement therapy (HRT) as a treatment option for women experiencing symptoms associated with perimenopause and menopause. The bill seeks to educate the public about the benefits and risks of HRT, thereby empowering women to make informed decisions regarding their health during these transitional phases.

Key Provisions

  • Awareness Campaign: The bill mandates the establishment of a public awareness campaign that will provide information on:

    • The symptoms of perimenopause and menopause.
    • The role of hormone replacement therapy in alleviating these symptoms.
    • Potential benefits and risks associated with HRT.

  • Target Audience: The campaign is designed to reach women experiencing perimenopause and menopause, healthcare providers, and the general public.

Impact

  • Affected Groups:

    • Women undergoing perimenopause and menopause who may benefit from HRT.
    • Healthcare professionals who will receive updated information to better assist their patients.
    • The general public, which will gain a broader understanding of women's health issues related to menopause.

  • Health Outcomes: By increasing awareness and understanding of HRT, the bill aims to improve health outcomes for women by promoting informed discussions between patients and healthcare providers.

Legislative Timeline

  • January 13, 2025: Bill introduced and referred to the Women's Issues Committee.
  • January 21, 2025: Passed in the Senate and delivered to the Assembly.
  • June 4, 2025:
    • Passed in the Assembly.
    • Substituted for companion bill A 2698.
    • Ordered to third reading in the Rules Committee.
  • October 9, 2025: Delivered to the Governor.
  • October 16, 2025: Bill was vetoed.

Related Bills

  • A 2698: This is the companion bill to S 1720, which may contain similar provisions or objectives.

Conclusion

Bill S 1720 aimed to enhance awareness and understanding of hormone replacement therapy for women experiencing menopause and perimenopause. Despite its potential benefits, the bill was ultimately vetoed, preventing the proposed campaign from being implemented.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.